Alfred Gilman
Completion of a draft of the human genome and advances in gene expression manipulation imply the potential capacity to predict altered behavior from factors such as pharmacological inputs. In an age where collaborations and joint ventures are typical, a Nobel laureate in biomedicine will lead a research alliance that ultimately should promote faster disease treatment via targeted drug remedies. Alfred Gilman, chairman of pharmacology at the University of Texas Southwestern at Dallas, will act as steering committee chair for a newly formed Alliance for Cellular Signaling (AFCS).

The focus of the AFCS is to study the way cells communicate with each other to determine their functions and actions. Gilman received the 1994 Nobel Prize in physiology or medicine for his work with G proteins, which are a critical part of the "cellular switchboard." Multicellular organisms, such as mammals, have many different types of cells whose activities have...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?